A Phase 1/2 interventional study of GC3111B and Boostrix® in Tetanus-diphtheria-acellular Pertussis (Tdap), sponsored by GC Biopharma Corp. Recruiting at 1 site in South Korea. Open to participants aged 19 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-10.
Sponsored by GC Biopharma Corp · Phase 1/2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Diphtheria with a site in Korea, Republic of — 1 open to participants now, 1 under way, none of them phase 3. Diphtheria · Korea, Republic of.
Among the 19 studies in Diphtheria with a site in Korea, Republic of, this one is the 14th largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2025, is one of 2 in phase 1/2, and was the 19th registered.
268 studies on the registry are indexed under Diphtheria; 18 are open to participants now.
Browse Diphtheria studies →1 of the 19 studies in Diphtheria with a site in Korea, Republic of is open now.
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 11 Diphtheria studies recruiting now, 2 (18%) set no upper age limit and 9 (82%) stop at 75 or younger; 7 take children under 18; 10 take healthy volunteers.
This study: 19 Years to 64 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 10 · Phase 4 2
First in 2003; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 120 is below the median of 449 across 242 interventional studies indexed under Diphtheria.
Median enrollment 340 across the 16 interventional studies, 682 across the 3 observational. Of the 15 that completed or were terminated, 7 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 19 have an industry lead sponsor. The 8 most frequent:
This study is registered under GC Biopharma Corp, one of the names counted as GC Biopharma Corp.. Under that name alone:
GC Biopharma Corp is the lead sponsor of 16 studies on the registry; 6 are open to participants now.
GC Biopharma Corp. has 3 studies filed under Diphtheria — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 19 studies in Diphtheria with a site in Korea, Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This clinical trial consists of two parts: Part 1, which explores safety, and Part 2, which examines both safety and efficacy (immunogenicity). Part 1 is a single-center, open-label, single-group study, while Part 2 is designed as a multicenter, double-blind, randomized, active-controlled trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to receive a single dose of GC3111B vaccine.
Biological: GC3111B
Participants randomized to receive a single dose of Boostrix® vaccine.
Biological: Boostrix®
0.5 mL, Intramuscular injection
0.5 mL, Intramuscular injection
Solicited adverse events occurring by day 14 after administration of the investigational product
Time frame: 14 days after administration of the IP
Unsolicited adverse events occurring by day 28 after administration of the investigational product
Time frame: 28 days after administration of the IP
Acute adverse events occurring within 30 minutes after administration of the investigational product
Time frame: 30 minutes after administration of the IP
Serious adverse events (SAE) and adverse events of special interest (AESI) occurring up to 180 days after administration of the investigational product
Time frame: 180 days after administration of the IP
Clinically significant findings in vital signs, laboratory tests, 12-lead electrocardiograms, and physical examinations
Time frame: 28 days after administration of the IP
Antibody rates for diphtheria and tetanus on day 28 after administration of the investigational product
Time frame: 28 days after administration of the IP
Boosting response rates for diphtheria, tetanus, and pertussis on day 28 after administration of the investigational product
Boosting response rate: 1) If less than 0.1 IU/ml before vaccination, it should be 0.4 IU/ml or higher after the vaccination, or 2) if not less than 0.1 IU/ml before vaccination, it should be 4 times or higher after the vaccination.
Time frame: 28 days after administration of the IP
Geometric mean concentrations (GMC) of antibodies against diphtheria, tetanus, and pertussis antitoxins (anti-PT, anti-FHA, anti-PRN) on day 28 after administration of the investigational product
Time frame: 28 days after administration of the IP
Started Jun 2025 (actual). Primary completion is estimated for May 2026, 11 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.